Homozygous deletion of the methylthioadenosine phosphorylase (MTAP) is frequently found in some types of cancer, and the application of purine analogue has been shown to be effective therapeutic option in MTAP deletion cancer patients (Tang et al., 2018). This evidence concerns the gene MTAP and cancer.